Celltrion, Inc. (KRX: 068270)

Market Cap	39.46T
Revenue (ttm)	2.67T
Net Income (ttm)	323.33B
Shares Out	206.36M
EPS (ttm)	1,849.52
PE Ratio	103.38
Forward PE	52.05
Dividend	500.00 (0.26%)
Ex-Dividend Date	n/a

Volume	482,311
Open	192,300
Previous Close	193,500
Day's Range	191,200 - 193,400
52-Week Range	138,500 - 241,000
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Celltrion

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,391
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 068270

Financial Performance

In 2023, Celltrion's revenue was 2.18 trillion, a decrease of -4.71% compared to the previous year's 2.28 trillion. Earnings were 535.65 billion, a decrease of -0.41%.